Amgen has entered into a definitive agreement to acquire deCODE Genetics for $415 million in cash. Headquartered in Reykjavik, Iceland, deCODE Genetics provides expertise in analyzing and understanding the link between the genome and disease susceptibility and has discovered genetic risk factors for diseases ranging from cardiovascular disease to cancer. The transaction, subject to customary closing conditions, is expected to close before the end of the year.   “deCODE Genetics has built a...